Toggle light / dark theme

Exposure to certain pollutants, like fine particles (PM2.5) and nitrogen oxides (NOx), during pregnancy and childhood is associated with differences in the microstructure of the brain´s white matter, and some of these effects persist throughout adolescence. These are the main conclusions of a study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by “la Caixa” Foundation. The findings, published in Environmental Research, highlight the importance of addressing air pollution as a public health issue, particularly for pregnant women and children.

An increasing amount of evidence suggests that air pollution affects neurodevelopment in children. Recent studies using imaging techniques have looked at the impact of air pollutants on the brain’s white matter, which plays a crucial role in connecting different brain regions. However, these studies were limited in that they only looked at one timepoint and did not follow the participants throughout childhood.

“Following participants throughout childhood and including two neuroimaging assessments for each child would shed new light on whether the effects of air pollution on white matter persist, attenuate, or worsen,” says ISGlobal researcher Mònica Guxens. And that is what she and her team did.

An achievement that was deemed impossible has successfully become accomplished. For the first time in history, DNA can be edited. One of the goals is to be able to get rid of genetic diseases. This whole concept in genomic science has opened up a whole new revolutionary way of dealing with such critical health issues. There is a possibility that illnesses that were once incurable have a chance to be curable.

MedlinePlus provides a definition and states that a collection of tools known as genome editing, or gene editing, allows researchers to alter an organism’s DNA. These technologies enable the addition, deletion, or modification of genetic material at specific genomic regions. A person’s DNA can be altered through gene editing to fix mistakes that lead to illnesses.

CRISPR-Cas9, short for CRISPR-associated protein 9 and clustered regularly interspaced short palindromic repeats, is a well-known example as one of the approaches used and developed by scientists to edit DNA. The scientific community is very excited about the CRISPR-Cas9 system since it is more accurate, efficient, quicker, and less expensive than existing genome editing techniques.

(Nanowerk Spotlight) In the world of athletic performance and outdoor sports, the gear athletes wear can make or break their ability to perform.


Smart nanofabric integrates impact protection, real-time health monitoring, and radiative cooling into a lightweight, durable textile for advanced sportswear.

My name is Asim, Global Product Marketing Lead for Peridot, and I’m excited to share some news about our Peridot franchise that I’m incredibly passionate about.

Virtual pets have long been a source of fun and entertainment. But what if they could help us recover from injuries and illnesses, too?

Today we’re announcing our partnership with Augment Therapy, a digital health company building accessible immersive exercise software for healthcare. Together, we aim to help people recover from injuries and illnesses faster by creating new Peridot-inspired experiences for physical rehabilitation use cases in pediatric and geriatric care. What makes this partnership truly exceptional is our shared vision: leveraging cutting-edge technology to encourage movement and promote well-being.

To access the video, kindly visit.


Dive into the fascinating world of GlycoRNA in this insightful video! GlycoRNA, a newly emerging field at the intersection of glycobiology and RNA research, explores how glycan modifications on RNA molecules can influence gene expression and cellular function. Join us as we break down the basics of glycoRNA, its role in health and disease, and its potential applications in medicine and biotechnology.
References: https://zfangcs.wordpress.com/2021/06
https://answers.childrenshospital.org
Thank You For Watching.
Please Like And Subscribe to Our Channel: / easypeasylearning.
Like Our Facebook Page: / learningeasypeasy.
Join Our Facebook Group: / 460057834950033
Support Our Channel: / supereasypeasy.

A school in Texas is revolutionizing the way students learn by going all-in on artificial intelligence. Its leaders are using the technology to educate students without the help of a traditional teacher. NBC’s Gadi Schwartz reports for TODAY.

» Subscribe to TODAY: / @today.

About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage \& our original web series.

Connect with TODAY Online!

Weight-maintaining hormone key to brain-signal transmission. A study more closely links obesity to dementia, finding that leptin, a hormone that helps maintain normal body weight, is associated with better signal-transmitting brain white matter in middle-aged adults.

New research is more closely linking obesity to dementia.

Higher levels of leptin, a hormone that helps maintain normal body weight, is associated with better signal-transmitting brain white matter in middle-aged adults, according to a study by The University of Texas Health Science Center at San Antonio (UT Health San Antonio).

At the recent annual International AIDS Conference, a startling presentation about the newest wonder drug in HIV prevention brought a raucous standing ovation.


But some of us in the public health community are now starting to wonder what all the cheering was about. Although the scientific results were impeccable, the process for translating those results into action for young women in Africa has been left to our imaginations. And if history is any guide, this could be a nightmare.

When the results first came out, Gilead, the manufacturer of lenacapavir, stated it was too early to discuss licensing and offering vague plans about its production and availability in Africa. Just recently, a second study among men who have sex with men and predominantly conducted in the Northern Hemisphere showed similarly promising results. While Gilead now says they have sufficient data to move ahead with licensing and manufacturing worldwide, they have offered no timeline to do so. Urgency to report trial results has not been mirrored by the urgency to provide access. Unanswered questions remain about why another study was needed to move ahead with approvals for use in African women, and if and when lenacapavir will be made available at an affordable price in the African region.

The drug, which has a manufacturing cost estimated at about $40 per year, is currently licensed as an HIV treatment for more than $42,000 per year in the United States. In South Africa, health care expenditures in the public sector are approximately $230 per person per year. Advocates and the study scientists have strongly urged Gilead to make lenacapavir swiftly available in sub-Saharan Africa at an affordable price. But with over 3,000 women infected with HIV each week in the region according to UNAIDS estimates, there is no time to waste.